TC
TGTX icon

TFS Capital’s TG Therapeutics TGTX Stock Holding History

TFS Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-14,883
Closed -$90K – 977
2016
Q2 		$90K Buy
+14,883
New +$121K 0.02% 873
2014
Q4 		– Sell
-28,201
Closed -$301K – 1144
2014
Q3 		$301K Sell
28,201
-318,841
-92% -$2.96M 0.03% 743
2014
Q2 		$3.26M Buy
347,042
+167,701
+94% +$1.07M 0.26% 90
2014
Q1 		$1.24M Buy
+179,341
New +$1.06M 0.08% 377

Other funds holding TGTX

BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

TFS Capital's TGTX Position: Q3 2016 in Review

TFS Capital sold out of TG Therapeutics (TGTX) in Q3 2016, closing a stake of 14,883 shares — an estimated $90K sold.

TFS Capital first reported a position in TGTX in Q1 2014 and held it in 4 quarters. The position peaked at $3.26M in Q2 2014. 77 funds tracked by Wall St. Rank hold TGTX as of Q3 2016.

  • TFS Capital reported no remaining TG Therapeutics position as of Q3 2016 after selling out during the quarter.
  • TFS Capital sold 14,883 TG Therapeutics shares in Q3 2016, an estimated $90K.
  • TFS Capital first reported a position in TG Therapeutics in Q1 2014 and held it in 4 quarters.
  • TFS Capital's TG Therapeutics position peaked at $3.26M in Q2 2014.
  • 77 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.